[1] KAUR G, HAN S J, YANG I, et al. Microglia and central nervous system immunity [J]. Neurosurg Clin North Am, 2010, 21(1): 43-51.
[2] GOLDMANN T, PRINZ M. Role of microglia in CNS autoimmunity [J]. Clin Develop Immunol, 2013, 2013(2): 208093.
[3] KETTENMANN H, HANISCH U K, NODA M, et al. Physiology of microglia [J]. Physiol Rev, 2011, 91(2): 461-553.
[4] NIMMERJAHN A, KIRCHHOFF F, HELMCHEN F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo [J]. Science, 2005, 308(5726): 1314-1318.
[5] SALTER M W, BEGGS S. Sublime microglia: expanding roles for the guardians of the CNS [J]. Cell, 2014, 158(1): 15-24.
[6] BEGGS S, SALTER M W. SnapShot: microglia in disease [J]. Cell, 2016, 165(5): 1294-1294.e1. doi: 10.1016/j.cell.2016.05.036.
[7] DEIERBORG T, ROYBON L, INACIO A R, et al. Brain injury activates microglia that induce neural stem cell proliferation ex vivo and promote differentiation of neurosphere-derived cells into neurons and oligodendrocytes [J]. Neuroscience, 2010, 171(4): 1386-1396.
[8] EIKELENBOOM P, STAM F C. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study [J]. Acta Neuropathol, 1982, 57(2-3): 239-242.
[9] MCGEER P L, ITAGAKI S, TAGO H, et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR [J]. Neurosci Lett, 1987, 79(1-2): 195-200.
[10] BHASKAR K, KONERTH M, KOKIKO-COCHRAN O N, et al. Regulation of tau pathology by the microglial fractalkine receptor [J]. Neuron, 2010, 68(1): 19-31.
[11] BAMBERGER M E, HARRIS M E, MCDONALD D R, et al. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation [J]. J Neurosci, 2003, 23(7): 2665-2674.
[12] STEWART C R, STUART L M, WILKINSON K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer [J]. Nat Immunol, 2010, 11(2): 155-161.
[13] HICKMAN S E, ALLISON E K, EL KHOURY J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer′s disease mice [J]. J Neurosci, 2008, 28(33): 8354-8360.
[14] HUANG N Q, HAI J, ZHOU S Y, et al. TLR4 is a link between diabetes and Alzheimer′s disease [J]. Behav Brain Res, 2017, 316:234-244.
[15] STEINER N, BALEZ R, KARUNAWEERA N, et al. Neuroprotection of Neuro2a cells and the cytokine suppressive and anti-inflammatory mode of action of resveratrol in activated RAW264.7 macrophages and C8-B4 microglia [J]. Neurochem Int, 2016, 95(10):46-54.
[16] FAHN S. Description of Parkinson′s disease as a clinical syndrome [J]. Annals New York Acad Sci, 2003, 991(1):1-14.
[17] ZHANG F, LIU J, SHI J S. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation [J]. Eur J Pharmacol, 2010, 636(1-3): 1-7.
[18] WANG Q, LIU Y, ZHOU J. Neuroinflammation in Parkinson′s disease and its potential as therapeutic target [J]. Transl Neurodegen, 2015, 4(19). doi: 10.1186/s40035-015-0042-0.
[19] TRAPP B D, NAVE K A. Multiple sclerosis: an immune or neurodegenerative disorder? [J]. Annual Rev Neurosci, 2008, 31(1):247-269. doi: 10. 1146/annurev. neuro. 30. 051606. 094313.
[20] MCMURRAN C E, JONES C A, FITZGERALD D C, et al. CNS remyelination and the innate immune system [J]. Front Cell Develop Biol, 2016, 4:38. doi: 10.3389/fcell.2016.00038.
[21] GLASS C K, SAIJO K, WINNER B, et al. Mechanisms underlying inflammation in neurodegeneration [J]. Cell, 2010, 140(6): 918-934.
[22] TURNER B J, TALBOT K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS [J]. Prog Neurobiol, 2008, 85(1): 94-134.
[23] HALL E D, OOSTVEEN J A, GURNEY M E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS [J]. Glia, 1998, 23(3): 249-256.
[24] KOMINE O, YAMANAKA K. Neuroinflammation in motor neuron disease [J]. Nagoya J Med Sci, 2015, 77(4): 537-549.
[25] TAI Y F, PAVESE N, GERHARD A, et al. Imaging microglial activation in Huntington′s disease [J]. Brain Res Bull, 2007, 72(2-3): 148-151.
[26] ROSAS H D, LEE S Y, BENDER A C, et al. Altered white matter microstructure in the corpus callosum in Huntington′s disease: implications for cortical "disconnection" [J]. Neuro Image, 2010, 49(4): 2995-3004.
[27] CROTTI A, GLASS C K. The choreography of neuroinflammation in Huntington′s disease [J]. Trends Immunol, 2015, 36(6): 364-373.
[28] SHI X M,RUAN Y Y,ZHANG L, et al. Effects of safflower yellow on inflammation reaction in the cortical of APP/PS1 transgenic mice [J]. Chin Pharm J (中国药学杂志), 2016, 51(7): 550-553.
[29] NIE X Q,ZHANG D D,ZHANG H. Inflammation, insulin resistance and traditional chinese medicine treatment of diabetes mellitus [J]. Chin Pharm J (中国药学杂志), 2017, 52(1): 1-7.
[30] GONG Q H, FEI L, FENG J, et al. Resveratrol attenuates neuroinflammation-mediated cognitive deficits in rats [J]. J Health Sci, 2010, 56(6): 655-663.
[31] CAPIRALLA H, VINGTDEUX V, ZHAO H, et al. Resveratrol mitigates lipopolysaccharide- and Abeta-mediated microglial inflammation by inhibiting the TLR4/NF-kappaB/STAT signaling cascade [J]. J Neurochem, 2012, 120(3): 461-472.
[32] CHEN J, ZHOU Y, MUELLER-STEINER S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling [J]. J Biol Chem, 2005, 280(48): 40364-40374.
[33] JIN F, WU Q, LU Y F, et al. Antagonistic effects of resveratrol on Parkinson′s disease model rats [J]. Acta Acad Med Zunyi (遵义医学院学报), 2009, 32(1): 10-12.
[34] JIN F, WU Q, LU Y F, et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson′s disease in rats [J]. Eur J Pharmacol, 2008, 600(1-3): 78-82.
[35] ZHANG F, SHI J S, ZHOU H, et al. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions [J]. Mol Pharmacol, 2010, 78(3): 466-477.
[36] MANCUSO R, DEL VALLE J, MODOL L, et al. Resveratrol improves motoneuron function and extends survival in SOD1(G93A)ALS mice [J]. Neurotherapeutics, 2014, 11(2): 419-432.
[37] NAIA L, ROSENSTOCK T R, OLIVEIRA A M, et al. Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington′s disease models [J]. Mol Neurobiol, 2017,54(7):5385-5399.
[38] GHAIAD H R, NOOH M M, EL-SAWALHI M M, et al. Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study [J]. Mol Neurobiol, 2017, 54(5):3219-3229.
[39] RADKAR V, LAU-CAM C, HARDEJ D, et al. The role of surface receptor stimulation on the cytotoxicity of resveratrol to macrophages [J]. Food Chem Toxicol, 2008, 46(12): 3664-3670.
[40] YOUN H S, LEE J Y, FITZGERALD K A, et al. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex [J]. J Immunol (Baltimore), 2005, 175(5): 3339-3346.
[41] JAKUS P B, KALMAN N, ANTUS C, et al. TRAF6 is functional in inhibition of TLR4-mediated NF-kappaB activation by resveratrol [J]. J Nutr Biochem, 2013, 24(5): 819-823.
[42] FENG Y, CUI Y, GAO J L, et al. Resveratrol attenuates neuronal autophagy and inflammatory injury by inhibiting the TLR4/NF-kappaB signaling pathway in experimental traumatic brain injury [J]. Int J Mol Med, 2016, 37(4): 921-930.
[43] JUNTTILA M R, LI S P, WESTERMARCK J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival [J]. FASEB J, 2008, 22(4): 954-965.
[44] MATSUZAWA A, SAEGUSA K, NOGUCHI T, et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity [J]. Nat Immunol, 2005, 6(6): 587-592.
[45] PAWATE S, SHEN Q, FAN F, et al. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma [J]. J Neurosci Res, 2004, 77(4): 540-551.
[46] ZHONG L M, ZONG Y, SUN L, et al. Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells [J]. PLoS One, 2012, 7(2): e32195.
[47] OKAWARA M, KATSUKI H, KURIMOTO E, et al. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults [J]. Biochem Pharmacol, 2007, 73(4): 550-560.
[48] YE J, LIU Z, WEI J, et al. Protective effect of SIRT1 on toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-caspase-3-dependent apoptotic pathway [J]. Neurosci Lett, 2013, 553(8):72-77.
[49] JIN F, WU Q, LU Y F, et al. Protective effect of resveratrol on Parkinson′s disease rats and mechanism research [J]. Acta Acad Med Zunyi (遵义医学院学报), 2009, 32(3): 222-224.
[50] SALMINEN A, HYTTINEN J M, KAARNIRANTA K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan [J]. J Mol Med, 2011, 89(7): 667-676.
[51] YI C O, JEON B T, SHIN H J, et al. Resveratrol activates AMPK and suppresses LPS-induced NF-kappaB-dependent COX-2 activation in RAW 264.7 macrophage cells [J]. Anatomy Cell Biol, 2011, 44(3): 194-203.
[52] PARK S J, AHMAD F, PHILP A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases [J]. Cell, 2012, 148(3): 421-433.
[53] JIN F, GONG Q H, XU Y S, et al. Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling [J]. Int J Neuropsychopharmacol, 2014, 17(6): 871-881.
[54] DELL′AGLI M, GALLI G V, VRHOVSEK U, et al. In vitro inhibition of human cGMP-specific phosphodiesterase-5 by polyphenols from red grapes [J]. J Agricul Food Chem, 2005, 53(6): 1960-1965.
[55] CHUNG J H. Metabolic benefits of inhibiting cAMP-PDEs with resveratrol [J]. Adipocyte, 2012, 1(4): 256-258.
[56] WANG C M, CHENG Y F, WU J G, et al. The new PDE4 inhibitor Roflupram ameliorated cognitive deficits and neuroinflammation in a rat model of Alzheimer′s disease [J]. Chin Pharmacol Bull (中国药理学通报), 2015, 31(3): 327-333.
[57] SCHAFER D, LEHRMAN E, KAUTZMAN A, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner [J]. Neuron, 2012, 74(4): 691-705.
[58] YAMAMOTO T, TAMAKI K, SHIRAKAWA K, et al. Cardiac Sirt1 mediates the cardioprotective effect of caloric restriction by suppressing local complement system activation after ischemia-reperfusion [J]. Am J Physiol Heart Circul Physiol, 2016, 310(8):1003-1014.
[59] SONG L, SONG W, SCHIPPER H M. Astroglia overexpressing heme oxygenase-1 predispose co-cultured PC12 cells to oxidative injury [J]. J Neurosci Res, 2007, 85(10): 2186-2195.
[60] JIN F, JIN H, SHI J S, et al. Effects of resveratrol on expression of iNOS mRNA and HO-1 mRNA of 6-OHDA induced chronic Parkinson′s disease rats [J]. Chin J New Clin Rem (中国新药与临床杂志), 2012, 31(1): 42-46.
[61] DILSHARA M G, LEE K T, KIM H J, et al. Anti-inflammatory mechanism of alpha-viniferin regulates lipopolysaccharide-induced release of proinflammatory mediators in BV2 microglial cells [J]. Cell Immunol, 2014, 290(1): 21-29.
[62] STEELE M L, FULLER S, PATEL M, et al. Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells [J]. Redox Biol, 2013, 1(1):441-445.
[63] CAHILL-SMITH S, LI J M. Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: a role of NADPH oxidase 2 [J]. Br J Clin Pharmacol, 2014, 78(3): 441-453.
[64] CHENG P W, HO W Y, SU Y T, et al. Resveratrol decreases fructose-induced oxidative stress, mediated by NADPH oxidase via an AMPK-dependent mechanism [J]. Br J Pharmacol, 2014, 171(11): 2739-2750.